-
Mashup Score: 1
A practical guide for GPs to help in the detection and diagnosis of myeloma and monoclonal gammopathies. It focuses on the tests used in primary care if myeloma is suspected, how to interpret test results, and guidance on when a referral to haematology may be needed.
Source: new-learning.bmj.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens - 3 year(s) ago
The treatment landscape for multiple myeloma has evolved rapidly in recent years. Introduction of proteasome inhibitors [1-4], immunomodulatory drugs [5,6], and antibody therapies [7,8] have significantly prolonged the life expectancy of patients with multiple myeloma, especially when combined with high-dose chemotherapy and autologous hematopoietic cell transplantation (auto-HCT) [9,10]….
Categories: Hem/Oncs, Latest HeadlinesTweet-
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens https://t.co/pc0JWiVvgp Poorer outcomes in high risk and relapsed disease, the very patients that are referred for an allo.
-
-
Mashup Score: 1
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)-based vaccines are ~95% effective in preventing coronavirus disease 20191–5. The dynamics of antibody secreting plasmablasts (PBs) and germinal centre (GC) B cells induced by these vaccines in humans remain unclear. We examined antigen-specific B cell responses in peripheral blood (n=41) and draining lymph nodes…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @PLMcCarthyMD: https://t.co/DuANHLFUwO
-
-
Mashup Score: 30COVID-19: in the footsteps of Ernest Shackleton - 4 year(s) ago
We describe what we believe is the first instance of complete COVID-19 testing of all passengers and crew on an isolated cruise ship during the current COVID-19 pandemic. Of the 217 passengers and crew on board, 128 tested positive for COVID-19 on reverse transcription–PCR (59%). Of the COVID-19-positive patients, 19% (24) were symptomatic; 6.2% (8) required medical evacuation; 3.1% (4) were…
Source: ThoraxCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VincentRK: Here is a link to the full paper. https://t.co/BLfH8itAfc
-
-
Mashup Score: 5
Highlights•The immune microenvironment in the post-high dose chemotherapy and autologous stem cell transplant stage is characterized by reduction in T-regs with increased CD8+ cytotoxic lymphocytes thus meriting the evaluation of checkpoint inhibitor-based consolidation in this setting in multiple myeloma.•This clinical trial enrolled newly diagnosed multiple myeloma patients who did not achieve…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @MeeraMohanMD: Long term follow up of newly diagnosed multiple myeloma patients treat... https://t.co/eYeKrccaxx @adsouza_md @Phari @SCh…
-
-
Mashup Score: 118-month follow-up on CARTITUDE-1 - 4 year(s) ago
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, gives an update on the CARTITUDE-1 (NCT03548207)…
Source: VJHemOncCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @VJHemOnc: For more on CARTITUDE-1, watch our interview with @szusmani (@UNC_SOM) 👉https://t.co/1hQdG8OgvD👈 @EHA_Hematology #EHA2021 @…
-
-
Mashup Score: 2FDA Grants Breakthrough Therapy Designation for Teclistamab to Treat Relapsed, Refractory Multiple Myeloma - 4 year(s) ago
Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors.
Source: Pharmacy TimesCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @grpetersen1: https://t.co/BWpYvzJKAx
-
-
Mashup Score: 1
Leading physicians, together with patients and patient advocates, explore the potential of measurable or minimal residual disease (MRD) as a new endpoint to …
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
What is the value of #MRD testing in #multiplemyeloma & what does it mean for pts? Watch doc to hear from experts inc. @Mohty_EBMT & @MyelomaEurope 👉 https://t.co/bx5QVUgILH 👈 #mmsm #MRDdoc #ASH19 @JanssenEMEA
-
-
Mashup Score: 0Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability - 4 year(s) ago
Multiple myeloma (MM) cells consume huge amounts of glutamine and, as a consequence, the amino acid concentration is lower-than-normal in the bone marrow (BM) of MM patients. Here we show that MM-dependent glutamine depletion induces glutamine synthetase in stromal cells, as demonstrated in BM biopsies of MM patients, and reproduced in vitro by co-culturing human mesenchymal stromal cells (MSCs)…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability https://t.co/5aiSkVpNpI # via @MDPIOpenAccess ....one reason osteoblasts don’t repair bone in patients with active myeloma
-
-
Mashup Score: 0
Multiple myeloma is a malignancy of plasma cells, which is highly associated with immune suppression. Consistent with this, reports of outcomes of COVID-19 infection in patients with multiple myeloma show higher rates of severe disease than in the general population.1,2 Protection of this vulnerable patient group from COVID-19 infection is crucial but response to the new vaccines in patients with…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma https://t.co/DQVH2jEym1 Some encouraging early data on the response of nearly 100 myeloma patients treated at the Royal Marsden to the first dose of vaccination against covid 19.
-
Our BMJ Myeloma module has had a strong start with 430 completions since the launch on Sept 1st 😊 with a number of nice and kind reviews coming through – a great collaboration https://t.co/B4TfPtzB2o @MyelomaUK @BMJLearning